Equity Overview
Price & Market Data
Price: $1.01
Daily Change: +$0.01 / 0.99%
Daily Range: $0.97 - $1.03
Market Cap: $107,102,232
Daily Volume: 300,858
Performance Metrics
1 Week: -1.99%
1 Month: -6.61%
3 Months: -19.52%
6 Months: 6.45%
1 Year: 31.72%
YTD: 20.91%
Company Details
Employees: 72
Sector: Health technology
Industry: Medical specialties
Country:
Details
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.